Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo.
Pain Research Forum: application of scientific social media frameworks in neuroscience.
Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients.
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
Homophilic interaction of the L1 family of cell adhesion molecules.
Melatonin pathway genes are associated with progressive subtypes and disability status in multiple sclerosis among Finnish patients.
Substance Name: Dronabinol
The autonomic balance predicts cardiac responses after the first dose of fingolimod.
Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.
Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden.
Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis.
Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.
A cross-sectional study examining multiple mobility device use and fall status among middle-aged and older adults with multiple sclerosis.
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Unprovoked seizures in multiple sclerosis and systemic lupus erythematosus: A population-based case-control study.
Heat shock protein 27 in multiple sclerosis relapses.
Self-management for people with long-term neurological conditions.
Birth outcomes of pregnancies fathered by men with multiple sclerosis.
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.
1,25-Dihydroxyvitamin D3 selectively and reversibly impairs T helper-cell CNS localization.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
Structure of the first sphingosine 1-phosphate receptor.
Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression

Pages